Pharvaris
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing with new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.
Domain
pharvaris.com
Country
SwitzerlandIndustry
BiotechnologyEmployees
101-250
Last Funding
$201.2M
Founded
2014
Tech Stack (26 technologies)
Frequently Asked Questions
What technologies does Pharvaris use?+
Pharvaris uses 26 technologies including AOS, Bootstrap, Facebook Pixel.
What industry is Pharvaris in?+
Pharvaris operates in the Biotechnology industry.
Where is Pharvaris based?+
Pharvaris is headquartered in Switzerland.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026